Front Neuroanat:药物治疗下HIV依旧破坏儿童脑部

2017-10-18 海北 MedSci原创

由于指南和治疗方式的改变,更多的艾滋病毒感染儿童在婴儿期开始抗逆转录病毒疗法(ART)。但是至今为止,很少有研究检查围产期艾滋病毒感染和早期ART对神经发育的长期影响。

由于指南和治疗方式的改变,更多的艾滋病毒感染儿童在婴儿期开始抗逆转录病毒疗法(ART)。但是至今为止,很少有研究检查围产期艾滋病毒感染和早期ART对神经发育的长期影响。在艾滋病毒和抗逆转录病毒治疗存在的情况下,我们还需要更多的研究来探索大脑的发育成熟过程。艾滋病毒感染(HIV)儿童的后续研究对于监测艾滋病毒感染和抗病毒治疗中大脑的发育情况至关重要。 使用扩散张量成像(DTI)的方法,来自开普敦大学的研究人员检查了65例HIV阳性儿童和46例对照组(HIV暴露未感染(HEU)和HIV未暴露未感染(HU))7岁儿童的白质(WM)。 这是一个5年队列研究的后续研究。研究人员之前就发现,和对照组相比,HIV阳性儿童皮质脊髓束(CST)中部分各向异性(FA)减弱,而在下/上纵束(ILF / SLF),额枕下束 (IFOF),和钩束(UF)中平均扩散系数(MD)有所增加。此外,研究人员还发现ART开始的年龄不同,FA会存在差异。 在此次的研究中,研究人员发现,和对照组相比,7岁的HIV阳性儿童在左侧IFOF和左侧LIF的两个区域中的FA较低。在IFOF相似的区域,辐射冠上部(SCR),丘脑放射前部

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1882541, encodeId=848f1882541e2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 02 00:39:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633392, encodeId=788216333921d, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Sep 11 19:39:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254018, encodeId=de932540185c, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Oct 18 13:03:17 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253989, encodeId=8bc5253989c4, content=学习啦!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed Oct 18 09:50:20 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253949, encodeId=775a253949d3, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Oct 18 07:50:17 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2018-06-02 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1882541, encodeId=848f1882541e2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 02 00:39:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633392, encodeId=788216333921d, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Sep 11 19:39:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254018, encodeId=de932540185c, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Oct 18 13:03:17 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253989, encodeId=8bc5253989c4, content=学习啦!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed Oct 18 09:50:20 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253949, encodeId=775a253949d3, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Oct 18 07:50:17 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2018-09-11 AspirantSuo
  3. [GetPortalCommentsPageByObjectIdResponse(id=1882541, encodeId=848f1882541e2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 02 00:39:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633392, encodeId=788216333921d, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Sep 11 19:39:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254018, encodeId=de932540185c, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Oct 18 13:03:17 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253989, encodeId=8bc5253989c4, content=学习啦!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed Oct 18 09:50:20 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253949, encodeId=775a253949d3, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Oct 18 07:50:17 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2017-10-18 1dd8c52fm63(暂无匿称)

    了解了解.学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1882541, encodeId=848f1882541e2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 02 00:39:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633392, encodeId=788216333921d, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Sep 11 19:39:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254018, encodeId=de932540185c, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Oct 18 13:03:17 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253989, encodeId=8bc5253989c4, content=学习啦!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed Oct 18 09:50:20 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253949, encodeId=775a253949d3, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Oct 18 07:50:17 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2017-10-18 tanxingdoctor

    学习啦!谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1882541, encodeId=848f1882541e2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 02 00:39:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633392, encodeId=788216333921d, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Sep 11 19:39:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254018, encodeId=de932540185c, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Oct 18 13:03:17 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253989, encodeId=8bc5253989c4, content=学习啦!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed Oct 18 09:50:20 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253949, encodeId=775a253949d3, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Oct 18 07:50:17 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2017-10-18 Y—xianghai

    学习了新知识

    0

相关资讯

J INFECT DIS实现国家艾滋病毒/艾滋病战略将挽救患者生命

由马萨诸塞州总医院(MGH)调查人员组成的分析显示,到2020年实现国家艾滋病战略(NHAS)的治疗目标,不仅可以防止数十万新的感染和死亡,而且还将显示出卓越的价值。他们在“传染病杂志”上发表的研究发现,符合NHAS目标--90%的艾滋病毒感染者知道他们的诊断,其中80%通过抗逆转录病毒药物治疗(ART)实现病毒学抑制。

MMWR:研究显示,大部分艾滋病儿童得不到救治,会不会成为新的危机?

近期的一篇在线文章引起了关注,文章的主要内容是关于发病率和死亡率的报告,研究显示,很大一部分诊断为艾滋病的儿童无法接受治疗。

Scient Rep:“根除”艾滋病毒的新方法

近年来,艾滋病的治疗方法与日俱进,但是谈到根治始终有一段很远的距离。日前,日本熊本大学的研究人员开发了一种新的化合物,是破坏艾滋病病毒的关键。化合物引入感染细胞时,从而围在宿主细胞周围的病毒释放,然后通过细胞凋亡的过程,细胞自然死亡。这种疗法是可以使艾滋病在不久的将来的完全恢复的希望。

上海药店开售艾滋病唾液快检试剂,10-15分钟出结果

9月29日,上海市HIV快检试剂药店销售项目在上海静安区雷允上药城召开,这标志着HIV(艾滋病病毒)唾液快检试剂药店销售的试点工作在本市正式启动。

Lancet Glob Health:降低HIV死亡率,这项措施尤为重要!

在ANRS TEMPRANO试验中的长期随访研究证实,艾滋病毒感染者的结核病化学预防在资源有限的国家比以往任何时候都更为重要。药物的这种预防性使用降低死亡率,即使在接受抗逆转录病毒治疗的CD4 + T细胞计数较高的人群中。 ANRS TEMPRANO由象牙海岸ANRS网站的研究人员进行,该网站包括来自Inserm(U1219,波尔多大学),Treichville大学医院感染和热带病系以及其他八个在

J Urban Health:艾滋病毒传播与种族/民族/地域差异之间的联系

人们生活,工作和健康有很好的记录,以及旨在改善健康的邻里级结构性干预措施有很大的价值。但是,导致艾滋病毒传播和疾病负担差距的基于地方特征的了解甚少,这可能导致减少艾滋病毒的干预措施和计划编制效率低下。